A carregar...
Moxifloxacin in the Initial Therapy of Tuberculosis: A Randomized, Phase 2 Trial
BACKGROUND: New therapies are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that may have additive activity to existing antituberculosis agents. We conducted a Phase 2 clinical trial to determin...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2866651/ https://ncbi.nlm.nih.gov/pubmed/19345831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(09)60333-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|